Inhibrx, Inc. (INBX) Tops Q1 EPS by 421c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall St set for higher open as Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts INBX Hot Sheet
Join SI Premium – FREE
Inhibrx, Inc. (NASDAQ: INBX) reported Q1 EPS of $2.80, $4.21 better than the analyst estimate of ($1.41).
For earnings history and earnings-related data on Inhibrx, Inc. (INBX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Reiterates Market Perform Rating on Dine Brands (DIN)
- Bernstein SocGen on Neurocrine Bio. (NBIX): 'This latest Crenessity beat may serve as the positive inflection point'
- Abbvie (ABBV) PT Raised to $340 at BMO Capital
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
